Inventor · disambiguated record
Frederick Joseph Schnell
Also filed as: SCHNELL FREDERICK J · SCHNELL FREDERICK JOSEPH
10 granted patents·21 pending applications·12 citations·filing 2011–2025
83Inventor score
Top patents by PatentIndex Score
31 records- 0190US2025236869A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0289US10758629B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2018·Granted Sep 1, 2020·2 cites·4 claims
- 0386US11338041B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2020·Granted May 24, 2022·1 cites·22 claims
- 0486US10765760B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2018·Granted Sep 8, 2020·1 cites·4 claims
- 0581US2024042049A1Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0681US2025171779A1Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase geneSAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0780US2023110479A1Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0879US9238042B2Antisense modulation of interleukins 17 and 23 signalingSCHNELL FREDERICK J·Filed 2011·Granted Jan 19, 2016·8 cites·24 claims
- 0979US2025171783A1Antisense-induced exon2 inclusion in acid alpha-glucosidaseSAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1077US2022056442A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1175US11491238B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2020·Granted Nov 8, 2022·0 cites·17 claims
- 1275US2025179487A1Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1375US2023407301A1Antisense oligomer compoundsSAREPTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1475US2025090569A1Exon skipping oligomers and oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1575US2025092393A1Exon skipping oligomers and oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1673US12139709B2Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase geneSAREPTA THERAPEUTICS INC·Filed 2021·Granted Nov 12, 2024·0 cites·16 claims
- 1772US2024344067A1Exon skipping oligomers for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1868US11555189B2Antisense oligomer compoundsSAREPTA THERAPEUTICS INC·Filed 2018·Granted Jan 17, 2023·0 cites·9 claims
- 1967US2025290069A1Exon skipping oligomers for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2065US2022017901A1Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2161US2022090084A1Antisense-induced exon exclusion in myostatinSAREPTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2261US2021220386A1Exon skipping oligomers and oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2360US2022251551A1Exon skipping oligomers for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2459US11060089B2Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase geneSAREPTA THERAPEUTICS INC·Filed 2017·Granted Jul 13, 2021·0 cites·8 claims
- 2559US11015200B2Antisense-induced exon exclusion in myostatinSAREPTA THERAPEUTICS INC·Filed 2016·Granted May 25, 2021·0 cites·14 claims
- 2659US2021283170A1Methods and compounds for treatment of lymphocyte-related diseases and conditionsSAREPTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2758US2022364084A1Exon skipping oligomers for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2857US2020190516A1Exon skipping oligomer conjugates for muscular dystropySAREPTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2956US2021102205A1Exon skipping oligomers and oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3044US2018216111A1Antisense-induced exon2 inclusion in acid alpha-glucosidaseSAREPTA THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3142US11020417B2Methods and compounds for treatment of lymphocyte-related diseases and conditionsSAREPTA THERAPEUTICS INC·Filed 2016·Granted Jun 1, 2021·0 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when Frederick Joseph Schnell files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →